Ras
Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.
Ras Isoform Specific Products
All Product Categories
-
Ras Related Products (719)
Related Products (719)
-
Antibodies (36)
-
Ras Isoform Comparison
-
KRAS G12C inhibitor 27
0 ImagesCat. No.: HY-142458CAS No.: 2648584-51-2KRAS G12C inhibitor 27 is a KRAS G12C inhibitor with antitumor effects (WO2021109737).
-
NMac1
0 ImagesCat. No.: HY-115507CAS No.: 1332290-68-2NMac1 is an orally active Nm23/NDPK activator. NMac1 directly binds to Nm23-H1 and activates the NDPK activity of recombinant Nm23-H1 with an EC50 of 10.7 uM. NMac1 induces AMPK activation and inhibits mTOR and ERK, leading to mitochondrial OXPHOS dysregulation and suppressing mitochondrial ROS production, which in turn induces mitochondrial dysfunction in MDA-MB-231 cells. NMac1 inhibits Complex I activity and suppresses changes in morphology and actin cytoskeleton organization following Rac1 activation in MDA-MB-231 cells. NMac1 inhibits tumor invasion, migration and metastasis. NMac1 is useful for studying metastatic tumors, such as breast cancer. NMac1 can be isolated from the ginger cassumunar Roxb.
-
SOS1-IN-8
0 ImagesCat. No.: HY-144212CAS No.: 2759387-92-1SOS1-IN-8 is a potent SOS1 inhibitor with IC50s of 11.6 and 40.7 nM for SOS1-G12D and SOS1-G12V, respectively (WO2022017339A1, compound 2).
-
KRAS G12D inhibitor 3
0 ImagesCat. No.: HY-115880CAS No.: 2757095-11-5KRAS G12D inhibitor 3 is a KRAS G12D inhibitor with an IC50 of <500 nM. KRAS G12D inhibitor 3 has antitumor effects (WO2022002102A1; compound 146). KRAS G12D inhibitor 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
Atranorin (Standard)
0 ImagesAtranorin (Standard) is the analytical standard of Atranorin (HY-N2907). This product is intended for research and analytical applications. Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC50 values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions.
-
G12Si-2
0 ImagesCat. No.: HY-150927CAS No.: 2946593-43-5G12Si-2, an analog of G12Si-1 (HY-150926), is a negative control tool. G12Si-2 is not a covalent inhibitor of the G12S mutant of K-Ras.
-
KRAS G12C inhibitor 5
0 ImagesCat. No.: HY-114168CAS No.: 2158297-63-1KRAS G12C inhibitor 5 is a KRas G12C inhibitor extracted from patent WO2017201161A1, Compound example 147.
-
KRAS G12C inhibitor 18
0 ImagesCat. No.: HY-132979CAS No.: 2649788-45-2KRAS G12C inhibitor 18 is a potent and orally active KRAS G12C inhibitor. Anti-tumor activities.
-
KRAS G12C inhibitor 13
0 ImagesCat. No.: HY-126292CAS No.: 2241719-75-3KRAS G12C inhibitor 13 is a KRAS G12C inhibitor extracted from patent WO2018143315A1, compound 30.
-
KRAS inhibitor-20
0 ImagesCat. No.: HY-151287CAS No.: 2411786-32-6KRAS inhibitor-20 is a small molecular inhibitor of KRasG12C, the oncogenic mutant. KRAS inhibitor-20 inhibits KRasG12C with the IC50 value <10 nM.
-
KRAS inhibitor-16
0 ImagesCat. No.: HY-146546CAS No.: 2230873-67-1KRAS inhibitor-16 (compound 3-11) is a potent KRAS G12C inhibitor with an IC50 of 0.457 µM. KRAS inhibitor-16 shows p-ERK inhibition activities with IC50s of 3.06, 11.1 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-16 has the potential for the research of pancreatic, colorectal, and lung cancers.
-
KRAS G12C inhibitor 17
0 ImagesCat. No.: HY-125875CAS No.: 2349393-04-8KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 82, has an IC50 of 5 nM.
-
BI-1388
0 ImagesCat. No.: HY-115516CAS No.: 1309952-03-1
-
KRAS inhibitor-4
0 ImagesCat. No.: HY-130260CAS No.: 2374152-69-7KRAS inhibitor-4 (compound F12) is a potent KRAS inhibitor and developed as anticancer agents.
-
AUBE00
0 ImagesCat. No.: HY-183553CAS No.: 2874214-01-2AUBE00 is an orally active, selective cyclic peptide pan-KRAS inhibitor. AUBE00 selectively binds to the OFF state of KRAS. AUBE00 exhibits anticancer activity against RAS wild-type colorectal cancer. The combination of AUBE00 with Cetuximab (HY-P9905) produces a synergistic antiproliferative effect.
-
KRAS inhibitor-14
0 ImagesCat. No.: HY-146544CAS No.: 2230873-78-4KRAS inhibitor-14 (compound 3-22) is a potent KRAS G12C inhibitor with an IC50 of 0.249 µM. KRAS inhibitor-14 shows p-ERK inhibition activities with IC50s of 1.12, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-14 has the potential for the research of pancreatic, colorectal, and lung cancers.
-
KRAS G12C inhibitor 16
0 ImagesCat. No.: HY-125874CAS No.: 2349392-79-4KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 39, has an IC50 of 97 nM.
-
KRAS G12V Peptide
0 ImagesCat. No.: HY-P11356CAS No.: 1932689-39-8KRAS G12V Peptide is a polypeptide and epitope derived from KRASG12V. KRAS G12V Peptide forms a stable, high-affinity peptide-HLA class I complex, which is processed and presented by tumor cells and can be recognized by specific TCR. KRAS G12V Peptide is applicable to research related to metastatic lung cancer.
-
KRASG12C IN-12
0 ImagesCat. No.: HY-159163CAS No.: 2093328-45-9KRASG12C IN-12 (compound-1) is a KRASG12C inhibitor. KRASG12C IN-12 (compound-1) can form a ternary complex with intracellular CYPA and the activated KRASG12C mutant.
